In September 2005, Procognia was awarded the 2005 Frost and Sullivan Competitive Strategy Leadership Award for its expanding portfolio of protein array based technologies
Procognia is helping to develop a fuller understanding of proteins as targets and as therapeutics and is currently working on a programme to array the human proteome in druggable classes.
Utilising technologies based around protein arrays, Procognia provides both the means for unravelling disease mechanisms and the discovery and development of drugs to treat those diseases.
Frost and Sullivan believes that Procognia has achieved outstanding and unparalleled success with these enabling protein array technologies and that the company is setting unprecedented trends for drug discovery research.
Procognia's success is based on its expertise in protein arrays that translates into its core technologies for drug screening and glycosylation analysis.
Procognia's protein arrays for drug screening are available either as catalogue themed arrays of functional human proteins exclusively via Sigma Aldrich, or directly from Procognia on a custom design basis.
Whatever the customer requirement, Procognia's proprietary tag technology ensures their protein function arrays increase their productivity by delivering fast and reproducible results.
Correct glycosylation is critical in the development of protein-based biopharmaceuticals and monitoring early in process development can increase the likelihood of the success of a drug in subsequent clinical trials.
Procognia's custom U-c Fingerprint technology removes the need for sample preparation and gives quantitative data in less than four hours, enabling near real-time glycosylation monitoring.
Researchers wishing to look at glycosylation patterns in a wide range of proteins will have access to this technology via a kit-based product supplied exclusively under license by Qiagen.
Frost and Sullivan analyst Charanya Ramachandran said: "One of biggest factors contributing to our decision to give Procognia this award was our recognition that several leading life science suppliers - namely Sigma-Aldrich, Qiagen and Perkin Elmer - had endorsed the value of this company's technologies by committing to marketing agreements and partnerships.
"Scientists in life science research, drug discovery and the industrial biopharmaceutical industry stand to benefit now that these products are commercially available".
Ron Long (CEO), Chris Lyddon (CFO) and Rachel Fallon (VP R+D and operations) were present to receive Procognia's award at the award banquet on 21 September 2005.
